Intelligence / Healthtech / New Clinical Trials / Hutchmed
Clinicaltrial registered3 Nov 2026
Hutchmed
3 Nov 2026: Trial registered · HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 3 Nov 2026
- Title
- HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
- Conditions
- Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07912398
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Hutchmed
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.